Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) on January 22 and set a price target of $51.00.
Mara Goldstein has given her Buy rating due to a combination of factors surrounding Arcus Biosciences’s recent data presentations and expectations for their clinical development. The updated information on the ARC-8 study involving the drug candidate, quemliclustat, in combination with other agents for the treatment of pancreatic cancer (PDAC), has shown promise. Her confidence stems from the observed consistency in overall survival (OS) rates between different treatment arms when accounting for baseline liver metastases, suggesting potential benefits from the addition of quemliclustat.
Further bolstering this perspective is the creation of a synthetic control arm (SCA), which serves as an innovative comparison tool for evaluating quemliclustat’s efficacy. The SCA indicated that quemliclustat outperformed external patients treated with the standard regimen in late-stage PDAC, exhibiting superior OS rates. This, coupled with positive performance across progression-free survival (PFS) and objective response rate (ORR), contributes to Goldstein’s optimistic outlook for Arcus Biosciences, underpinning her Buy recommendation despite the stock’s struggle to gain traction.
According to TipRanks, Goldstein is an analyst with an average return of -2.0% and a 35.35% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Adaptimmune Therapeutics, and Merck & Company.
In another report released on January 19, Barclays also assigned a Buy rating to the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS:
